NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions

COPD Exacerbation AcuteCOPD With Acute Lower Respiratory InfectionRhinovirusVirus DiseasesVirus Infection, RNAEnterovirusEnterovirus InfectionsRhinovirus InfectionInfection ViralRespiratory ComplicationRespiratory DiseaseRespiratory Tract InfectionsRespiratory Tract DiseasesRespiratory Viral InfectionUpper Resp Tract InfectionUpper Respiratory Tract InfectionsUpper Respiratory DiseaseUpper Respiratory DisorderUpper Respiratory Disease, AcuteUpper Respiratory Infection ViralInfections, RespiratoryInfectionsCopdViral InfectionEmphysema or COPDLower Respiratory DiseaseLower Respiratory DisorderLower Respiratory Tract and Lung InfectionsPulmonary DiseasePulmonary Disease, Chronic ObstructiveRespiratory Disease ChronicLung DiseasesLung Disease ChronicObstructive Pulmonary DiseaseChronic Lower Respiratory DiseasesChronic Respiratory Disease

Interventions

DRUG

Vapendavir

Participants randomized to the experimental cohort will be administered Vapendavir.

DRUG

Placebo

Participants randomized to the placebo cohort will be administered placebo.

Trial Locations (1)

W2 1NY

St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU), London